AIM ImmunoTech Inc

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

AIM ImmunoTech reports promising clinical progress and financial stability

AIM ImmunoTech demonstrated strong clinical progress and financial stability, positioning the company well for future growth and potential partnerships.
While facing regulatory and operational challenges, the company's focus on expanding Ampligen's therapeutic applications and medical expertise presents significant opportunities for advancement.
Investors should monitor AIM ImmunoTech's continued progress in clinical trials and regulatory interactions, as positive outcomes could drive value creation and market expansion.

AIM ImmunoTech reports positive clinical progress and solid financial standing

AIM ImmunoTech's Q2 2024 Earnings Call highlighted significant progress in clinical trials for Ampligen, particularly in oncology indications.
Financially, the company maintains a solid cash position and continues to manage expenses to support ongoing operations and future milestones.
While facing challenges in trial design and cost management, AIM ImmunoTech remains well-positioned to capitalize on opportunities for growth and partnership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OCALA, Fla. , Oct. 22, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, is scheduled to participate in a virtual panel titled, “COVID-19: Progress on Treatments & Prevention” on Thursday, October 29, at 10:05 A.M. Eastern Time at the 23rd Annual BioFlorida Conference. The presentation will be webcast live on the conference event platform, which can be accessed here.

AIM ImmunoTech CEO to Participate in Virtual Panel Presentation at the 23rd Annual BioFlorida Conference on October 29th

COVID-19 Patients May Continue to Experience Chronic Fatigue-Like Symptoms COVID-19 Patients May Continue to Experience Chronic Fatigue-Like Symptoms

AIM ImmunoTech Announces IRB Approval to Enroll COVID-19 ‘Long Haulers’ in the AMP-511 ME/CFS Clinical Trial of Ampligen

Aim ImmunoTech (AIM) is in the news Tuesday after positive results from an Early Access Program (EAP) sent AIM stock soaring higher.
The post Aim ImmunoTech News: Why AIM Stock Is Shooting 22% Higher Today appeared first on InvestorPlace.

Aim ImmunoTech News: Why AIM Stock Is Shooting 22% Higher Today

One of the things that's been keeping interest in AIM somewhat strong since that March plunge is that no company has pinned down an effective coronavirus treatment or vaccine. It's not a stretch to say some ambitious, risk-tolerant investors may be looking at AIM through the lens of the “door's open, why not AIM?

AIM ImmunoTech Seduces With Coronavirus Treatment Potential

Altimmune

Brighthouse Financial

SG Blocks

Soleno Therapeutics

As the Nasdaq continues its historic climb,  the Dow has erased some of Monday's gains. The coronavirus will continue to make headlines as its cases grow at a consistent rate across 23 states.

5 Stocks To Short As Markets Retreat From Monday’s Rally

Evoke Pharma

iBio

LiveXLive Media

Cheap stocks are effectively Wall Street's casino.

5 Cheap Stocks to Buy for $10 or Less

AIM stock has entered Wall Street’s consciousness due to the underlying biotech firm’s potential coronavirus treatment. However, will this be enough to keep shares moving higher?

2 Pros, 2 Cons for Buying AIM ImmunoTech

One big breakthrough moment in coronavirus research could bring wealth to AIM ImmunoTech. It could also bring big gains to AIM stock.

Coronavirus Research Is the Key for AIM ImmunoTech Stock

AIM ImmunoTech Inc. (NYSE: AIM) shares ticked higher on Thursday after the company announced some big developments with the U.S. Food and Drug Administration (FDA) concerning its treatment for cancer patients with COVID-19.

Will This COVID-19 Treatment for Cancer Patients Be a Big Hit?

Though AIM stock is relevant on paper, with competition raging in the race for a coronavirus treatment, along with AIM ImmunoTech's checkered past, this is a very speculative gamble.
The post AIM Stock Is a Moonshot That Lacks the Fuel appeared first on InvestorPlace.

AIM Stock Is a Moonshot That Lacks the Fuel

If it sounds too good to be true, it probably is. And that's likely the case when you look deeper into what's going on with AIM ImmunoTech stock.

Don’t Pull the Trigger on AIM ImmunoTech Stock

AIM ImmunoTech reported its 2019 results on March 31. Despite the coronavirus push, AIM stock headed lower on the news.

AIM Stock: You’ve Got a Better Shot of Getting Rich Buying a Lottery Ticket 

One of the few sectors that have enjoyed upside is the pharmaceutical industry. In particular, AIM stock has jumped on a possible Covid-19 treatment.

Read the Label Before Buying AIM Stock

AIM stock was a big winner on hopes it could join the response to the coronavirus. But its history suggests those hopes are too optimistic.

In the Coronavirus Vaccine Race, AIM Stock Isn’t a Likely Winner

Inovio Pharmaceuticals

Johnson & Johnson

Moderna

Novavax

Sanofi

Vir Biotechnology

Look for biotech stocks as a group to gain more than 20% this year … with the best, most innovative firms more than doubling.

Biotech Stocks: Coronavirus Response Shows How Far We’ve Come …

AIM ImmunoTech (AIM) news for Monday concerning a possible treatment for the coronavirus from China has AIM stock rocketing higher.

AIM ImmunoTech News: AIM Stock Skyrockets 208% on Hopes for COVID-19 Treatment

Cocrystal Pharma

Spherix

The major U.S. stock market averages were all tumbling close to 5% and bond yields were hitting record lows Monday following oil's plunge in the wake of the wrangling between Saudi Arabia and Russia.

3 Biotech Stocks Defying Today's Market Meltdown Thanks To COVID-19 Developments

Ampligen® obtained 100% survival rate at clinically achievable human dosage levels  for SARS in animal experiments

AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen® for Use Against the SARS-like Wuhan 2019 Novel Coronavirus

News for AIM ImmunoTech Inc Stock (AIM)